Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection

Summary

This study is to evaluate the safety and efficacy of umbilical cord mesenchymal stem cells Therapy for COVID-19.

Conditions

• COVID-19

Interventions

BIOLOGICAL

Umbilical cord mesenchymal stem cells implantation

Patient in Mscs group will receive MSCs implantation by intravenous injection.

OTHER

Comparator

Patients in comparator group will receive placebo treatment

Sponsors & Collaborators

• Hebei Medical University

  lead OTHER

Principal Investigators

• Xifeng Jiang, Doctor · The First Hospital of Hebei Medical University

• Gang Liu, Master · The First Hospital of Hebei Medical University

• Wuzhuang Sun, Master · The First Hospital of Hebei Medical University

• Baoyong Yan, Master · The First Hospital of Hebei Medical University

• Mingqi Zheng, Master · The First Hospital of Hebei Medical University

• Ding Yu, Master · The First Hospital of Hebei Medical University

• Le Wang, Master · The First Hospital of Hebei Medical University

• Yajie Wang, Master · The First Hospital of Hebei Medical University

• Quanhai Li, Master · The First Hospital of Hebei Medical University

• Xianyun Wang, Doctor · The First Hospital of Hebei Medical University

• Jiawei Yang, Postgraduate · The First Hospital of Hebei Medical University

• Tianshuo Li, Postgraduate · The First Hospital of Hebei Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-01-28

Primary Completion

2024-01-31

Completion

2025-01-31

Countries

• China

Study Locations